URGN•benzinga•
FDA Approves UroGen's ZUSDURI For Intravesical Solution As Medication For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga